Thrombospondin-1-derived peptide RFYVVMWK improves the adhesive phenotype of CD34sup+/sup cells from atherosclerotic patients with type 2 diabetes
| Autor: | Cointe , Sylvie, Rhéaume , Éric, Martel , Catherine, Blanc-Brude , Olivier, Dubé , Evemie, Sabatier , Florence, DIGNAT-GEORGE , Françoise, Tardif , Jean-Claude, Bonnefoy , Arnaud |
|---|---|
| Přispěvatelé: | Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Montreal Heart Institute - Institut de Cardiologie de Montréal, Université de Montréal (UdeM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Sainte Justine [Montréal], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), This work was supported in part by the Agence Nationale de la Recherche (Grant No. ANR-07-PHYSIO-025-02), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Vascular research center of Marseille ( VRCM ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de génétique et microbiologie [Orsay] ( IGM ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Institut Armand Frappier ( INRS-IAF ), Institut National de la Recherche Scientifique [Québec] ( INRS ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut Armand Frappier, Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Département de géographie, Université du Québec à Montréal ( UQAM ), Issekinicho Editions |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
MESH: Angina
Stable/metabolism MESH: Acute Coronary Syndrome/metabolism MESH: Diabetes Mellitus Type 2/immunology [SDV]Life Sciences [q-bio] MESH: Collagen/metabolism MESH: Diabetes Mellitus Type 2/metabolism MESH: Atherosclerosis/metabolism MESH: Peptides/chemistry MESH: Cell Adhesion/physiology MESH: Leukocytes Mononuclear/metabolism MESH: Acute Coronary Syndrome/immunology MESH: Atherosclerosis/immunology MESH: Platelet Aggregation Inhibitors/chemistry MESH: Human Umbilical Vein Endothelial Cells Type 2 diabetes (T2D) CD47 MESH: Aged MESH: Coronary Artery Disease/immunology MESH: Humans MESH: Middle Aged [ SDV ] Life Sciences [q-bio] MESH: Platelet Aggregation Inhibitors/pharmacology MESH: Peptides/pharmacology Atherosclerosis MESH: Male MESH: Coronary Artery Disease/metabolism MESH: Vitronectin/metabolism MESH: Angina Stable/immunology Thrombospondin-1 (TSP-1) MESH: Thrombospondin 1/chemistry MESH: Antigens CD34/metabolism CD34 MESH: Cells Cultured |
| Zdroj: | Cell Transplantation Cell Transplantation, Cognizant Communication Corporation, 2016, ⟨10.3727/096368916X693329⟩ Cell Transplantation, Cognizant Communication Corporation, 2016 |
| ISSN: | 0963-6897 |
| DOI: | 10.3727/096368916X693329⟩ |
| Popis: | International audience; Background: CD34(+) progenitor cells are growingly used for vascular repair. However, in diabetic individuals with cardiovascular diseases, these cells have dysfunctional engraftment capabilities, which compromise their use for autologous cell therapy. The thrombospondin-1-derived peptide RFYVVMWK has previously been reported to stimulate cell adhesiveness through CD47 and integrin activation pathways.Objectives: Our aim was to test whether RFYVVMWK preconditioning could modulate CD34(+) cells phenotype and enhance its pro-adhesive properties in diabetic patients.Patients/methods: Peripheral blood mononuclear CD34(+) cells isolated from 40 atherosclerotic patients with (T2D; n=20) or without (NonT2D; n=20) type 2 diabetes were pre-conditioned with 30µM of RFYVVMWK (or truncated peptide RFYVVM. CD34(+) cell adhesion was assessed on a vitronectin-collagen matrix and on a TNFα or IL-1β- stimulated HUVEC monolayers. Adhesion receptors, platelet/CD34(+) cell conjugates, and cell viability were analyzed by flow cytometry and confocal microscopy.Results: RFYVVMWK increased by 8 folds the adhesion of T2D CD34(+) cells to the vitronectin-collagen matrix (p Conclusions: Priming CD34(+) cells with RFYVVMWK may enhance their vascular engraftment during autologous pro-angiogenic cell therapy.. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|